aldosterone has been researched along with cardiovascular agents in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 12 (60.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angeli, P; Caregaro, L; Gatta, A; Lusiani, L; Menon, F; Merkel, C; Pagnan, A; Sacerdoti, D; Visoná, A | 1 |
| Burri, M; Kehtari, R; Metzger, J; Reuge, L | 1 |
| Espiner, EA; Frampton, CM; Nicholls, MG; Powell, JD; Rademaker, MT; Richards, AM; Troughton, RW; Yandle, TG | 1 |
| Konstam, MA | 1 |
| Pitt, B; Rajagopalan, S | 1 |
| Cascorbi, I; Kroemer, HK; Paul, M | 1 |
| Andreas, S; Delekat, A; Grunewald, RW; Hasenfuss, G; Lüthje, L; Reiter, H; Somers, VK | 1 |
| Mitka, M | 1 |
| Rahimtoola, SH | 1 |
| Calhoun, DA; Gaddam, KK; Husain, S; Pimenta, E | 1 |
| Felder, RB; Wei, SG; Yu, Y; Zhang, ZH | 1 |
| Miller, AB; Shafiq, MM | 1 |
| Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tanaka, T; Tsutamoto, T; Yamaji, M; Yamamoto, T | 1 |
| Charles, CJ; Nicholls, MG; Rademaker, MT; Richards, AM | 1 |
| Chen, CX; Gao, JP; Gu, WL; Lü, J; Wang, Y; Wu, Q | 1 |
| Nappi, JM; Sieg, A | 1 |
| Birner, C; Bratfisch, M; Dietl, A; Götz, T; Luchner, A; Riegger, GA; Schweda, F; Ulucan, C | 1 |
| Krum, H; Watanabe, M | 1 |
| Aimoto, M; Cao, X; Nagasawa, Y; Takahara, A; Zhang, CS; Zhang, HX | 1 |
| Garelli-Paar, C; Guillot, E; Mochel, JP; Prikazsky, M; Schneider, BK; Sotillo, S; Ward, J | 1 |
9 review(s) available for aldosterone and cardiovascular agents
| Article | Year |
|---|---|
[Chronic cardiac insufficiency: current treatment and future outlook].
Topics: Adrenergic Antagonists; Aldosterone; Angiotensin II; Cardiotonic Agents; Cardiovascular Agents; Clinical Protocols; Deoxyepinephrine; Digitalis Glycosides; Diuretics; Heart Failure; Humans; Vasoconstrictor Agents | 1996 |
Improving clinical outcomes with drug treatment in heart failure: what have trials taught?
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antidiuretic Hormone Receptor Antagonists; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Cytokines; Digoxin; Disease Progression; Drugs, Investigational; Endothelin Receptor Antagonists; Heart Failure; Humans; Risk; Survival Analysis; Treatment Failure; Treatment Outcome | 2003 |
Aldosterone as a target in congestive heart failure.
Topics: Aldosterone; Cardiovascular Agents; Endothelium, Vascular; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Myocardium; Plasminogen Activator Inhibitor 1; Progesterone; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome | 2003 |
Pharmacogenomics of heart failure -- focus on drug disposition and action.
Topics: Aldosterone; Cardiovascular Agents; Cytochrome P-450 Enzyme System; Heart Failure; Humans; Myocardium; Peptidyl-Dipeptidase A; Pharmacogenetics; Polymorphism, Genetic; Receptor, Angiotensin, Type 1; Renin-Angiotensin System | 2004 |
Aldosterone and cardiovascular disease.
Topics: Adrenalectomy; Aldosterone; Animals; Antihypertensive Agents; Cardiovascular Agents; Cardiovascular Diseases; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Kidney Diseases; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Treatment Outcome | 2009 |
Pharmacological treatment for heart failure: a view from the brain.
Topics: Aldosterone; Angiotensins; Animals; Blood-Brain Barrier; Brain; Cardiovascular Agents; Cell Communication; Cytokines; Drug Carriers; Drug Design; Heart Failure, Systolic; Humans; Inflammation; Sympathetic Nervous System | 2009 |
Blocking aldosterone in heart failure.
Topics: Aldosterone; Cardiovascular Agents; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
Topics: Aldosterone; Cardiovascular Agents; Chronic Disease; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Patient Selection; Receptors, Mineralocorticoid; Risk Assessment; Treatment Outcome | 2011 |
Eplerenone for the treatment of cardiovascular disorders.
Topics: Aldosterone; Animals; Cardiovascular Agents; Cardiovascular Diseases; Eplerenone; Humans; Hydrocortisone; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone | 2012 |
2 trial(s) available for aldosterone and cardiovascular agents
| Article | Year |
|---|---|
Effects of iloprost, a prostacyclin analog derivative, on renal plasma flow, renal function, and renin-aldosterone system in humans.
Topics: Aged; Aldosterone; Blood Pressure; Cardiovascular Agents; Clinical Trials as Topic; Epoprostenol; Heart Rate; Humans; Iloprost; Infusions, Intravenous; Kidney; Kidney Function Tests; Male; Middle Aged; Renal Circulation; Renin; Renin-Angiotensin System; Sodium | 1988 |
Differential effects of theophylline on sympathetic excitation, hemodynamics, and breathing in congestive heart failure.
Topics: Adolescent; Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Cardiovascular Agents; Endothelin-1; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Antagonists; Renin; Respiration; Single-Blind Method; Sleep Apnea, Central; Sympathetic Nervous System; Theophylline | 2004 |
9 other study(ies) available for aldosterone and cardiovascular agents
| Article | Year |
|---|---|
Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output; Cardiovascular Agents; Cross-Over Studies; Cyclic GMP; Disease Models, Animal; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Injections, Intravenous; Kidney; Natriuretic Peptide, Brain; Pyridines; Renin; Sheep; Sodium; Thiazepines | 2000 |
Scientists probe aldosterone's role in hypertension and heart disease.
Topics: Aldosterone; Cardiovascular Agents; Cardiovascular Physiological Phenomena; Heart Diseases; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoid Receptor Antagonists | 2004 |
Aldosterone and Cardiovascular Disease. Foreword.
Topics: Adrenalectomy; Aldosterone; Animals; Antihypertensive Agents; Cardiovascular Agents; Cardiovascular Diseases; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoid Receptor Antagonists | 2009 |
Effect of carperitide on plasma adiponectin levels in acute decompensated heart failure patients with diabetes mellitus.
Topics: Acute Disease; Adiponectin; Aged; Aldosterone; Atrial Natriuretic Factor; Biomarkers; Cardiovascular Agents; Diabetes Complications; Female; Heart Failure; Humans; Infusions, Parenteral; Linear Models; Male; Middle Aged; Natriuretic Peptide, Brain; Pilot Projects; Time Factors; Treatment Outcome; Up-Regulation | 2009 |
Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
Topics: Aldosterone; Animals; Biomarkers; Cardiac Pacing, Artificial; Cardiovascular Agents; Corticotropin-Releasing Hormone; Creatinine; Disease Models, Animal; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Hemodynamics; Infusions, Intra-Arterial; Kidney; Mice; Natriuresis; Potassium; Renin; Renin-Angiotensin System; Sheep; Time Factors; Urination; Urocortins; Vasopressins | 2009 |
Effects of polydatin on attenuating ventricular remodeling in isoproterenol-induced mouse and pressure-overload rat models.
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Abdominal; Blood Pressure; Cardiovascular Agents; Collagen; Cyclic AMP; Drugs, Chinese Herbal; Endothelin-1; Fallopia japonica; Glucosides; Heart; Hypertrophy, Left Ventricular; Isoproterenol; Male; Mice; Myocytes, Cardiac; Organ Size; Phytotherapy; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Stilbenes; Tumor Necrosis Factor-alpha; Ventricular Remodeling | 2010 |
Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Cardiovascular Agents; Disease Models, Animal; Gene Expression Regulation; Heart Failure; Male; Natriuretic Peptide, Brain; Neprilysin; Pyridines; Rabbits; Renin; Renin-Angiotensin System; RNA, Messenger; Tachycardia; Thiazepines; Ventricular Dysfunction, Left; Ventricular Remodeling | 2012 |
Electrophysiological Response to Acehytisine Was Modulated by Aldosterone in Rats with Aorto-Venocaval Shunts.
Topics: Aldosterone; Animals; Aorta; Arteriovenous Shunt, Surgical; Atrial Fibrillation; Atrial Remodeling; Cardiovascular Agents; Electrophysiological Phenomena; Heart Atria; Heterocyclic Compounds, 4 or More Rings; Male; Rats, Wistar; Venae Cavae | 2021 |
Breakthrough: a first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarkers; Cardiovascular Agents; Dogs; Heart Failure; Humans; Prospective Studies; Renin-Angiotensin System | 2023 |